Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | AGER | Q15109 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | DHODH | Q02127 | 3/20 | 0.38 |
| ▸ | MYC | P01106 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21957865 | 0.87 | TDP1 (0.42) | KDM4ETDP1ALDH1A1L3MBTL1ALOX15 | |
| SCHEMBL21957880 | 0.81 | KDM4E (0.44) | KDM4ETDP1ALDH1A1NPSR1MAPT | |
| SCHEMBL31245546 | 0.81 | KDM4E (0.44) | KDM4ETDP1ALDH1A1NPSR1MAPT | |
| SCHEMBL31245513 | 0.80 | KDM4E (0.42) | KDM4ETDP1ALDH1A1NPSR1MAPT | |
| SCHEMBL21957993 | 0.80 | KDM4E (0.42) | KDM4ETDP1ALDH1A1NPSR1MAPT | |
| SCHEMBL5741323 | 0.79 | KDM4E (0.52) | KDM4ETDP1ALDH1A1NPSR1MAPT | |
| SCHEMBL22018769 | 0.78 | KDM4E (0.41) | KDM4ETDP1ALDH1A1NPSR1MAPT | |
| Hydrochloric Acid SCHEMBL5741851 | 0.78 | KDM4E (0.50) | KDM4ETDP1ALDH1A1NPSR1MAPT | |
| SCHEMBL21958022 | 0.77 | LMNA (0.31) | SMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL16320724 | 0.76 | KDM4E (0.47) | KDM4ETDP1ALDH1A1NPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103454-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-16 | — | — | US | disclosed |
| CN-113316568-B | 2-Formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin | 全球血液疗法股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| US-20230159507-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159507-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159507-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11548880-B2 | Modulators of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11548880-B2 | Modulators of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4046988-A1 | 2-FORMYL-3-HYDROXYPHENYLOXYMETHYL COMPOUNDS CAPABLE OF MODULATING HEMOGLOBIN | Global Blood Therapeutics, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| EP-4046988-A1 | 2-FORMYL-3-HYDROXYPHENYLOXYMETHYL COMPOUNDS CAPABLE OF MODULATING HEMOGLOBIN | Global Blood Therapeutics, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| EP-3880654-B1 | 2-FORMYL-3-HYDROXYPHENYLOXYMETHYL COMPOUNDS CAPABLE OF MODULATING HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3880654-B1 | 2-FORMYL-3-HYDROXYPHENYLOXYMETHYL COMPOUNDS CAPABLE OF MODULATING HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3880654-A1 | 2-FORMYL-3-HYDROXYPHENYLOXYMETHYL COMPOUNDS CAPABLE OF MODULATING HEMOGLOBIN | Global Blood Therapeutics, Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| US-20210047309-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2021-02-18 | — | — | US | disclosed |
| US-20210047309-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2021-02-18 | — | — | US | disclosed |
| US-10683285-B2 | Modulators of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10683285-B2 | Modulators of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20200157085-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200157085-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157085-A1 | MODULATORS OF HEMOGLOBIN | HBG1, HBG2, HBB | KDM4E 1774/4885TDP1 3819/4885ALDH1A1 3168/4885 |
| US-10683285-B2 | Modulators of hemoglobin | HBG1, HBG2, HBB | KDM4E 1774/4885TDP1 3819/4885ALDH1A1 3168/4885 |
| US-20210047309-A1 | MODULATORS OF HEMOGLOBIN | HBG1, HBG2, HBB | KDM4E 1774/4885TDP1 3819/4885ALDH1A1 3168/4885 |
| US-20230159507-A1 | MODULATORS OF HEMOGLOBIN | HBG1, HBG2, HBB | KDM4E 1774/4885TDP1 3819/4885ALDH1A1 3168/4885 |
| US-20260103454-A1 | MODULATORS OF HEMOGLOBIN | HBZ, HBB, HBG2 | KDM4E 799/4885TDP1 3514/4885ALDH1A1 1843/4885 |
| US-11548880-B2 | Modulators of hemoglobin | HBG1, HBG2, HBB | KDM4E 1774/4885TDP1 3819/4885ALDH1A1 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.